Dublin, July 13, 2018 (GLOBE NEWSWIRE) -- The "Cognition and Memory Enhancement Drugs: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. This research report presents an in-depth analysis of the global cognition and memory-enhancing drugs market by application, product categories, and regional markets. The report includes key cognition drugs that are incorporated in several therapeutic treatment methods. It discusses the role of supply chain members from manufacturers to researchers. The report has an in-depth analysis of key companies operating in the global cognition and memory-enhancing drugs market. In-depth patent analysis in the report will focus on providing extensive technological trends across years and regions such as the U.S., Europe, and China. The cognition and memory-enhancing drugs market is segmented mainly into eight components: Aricept, Exelon, Reminyl, Namenda, Adderall, Ritalin, Dexedrin, and other cognition drugs. This market is further segmented on the basis of applications, which helps in understanding the potency of these memory enhancers in several therapeutic treatments. The market study is detailed for products based on applications as well as its further implication on the research and development area. These two segmentations are also discussed in detail for the given period. The market is segmented by region into the North America, Europe, Asia-Pacific, and ROW. Report Scope
- An overview of the global market for cognition and memory enhancement drugs
- Analyses of global market trends, with data from 2016 to 2017, and projections of compound annual growth rates (CAGRs) through 2022
- An overview of the ethics and side effects of cognition and memory enhancement drugs
- Market analyses by application, product, and region
- Assessment of patent litigation claims
- Insight into the competitive landscape, including mergers and acquisitions and new product launches
- Profiles of key companies in the market, including Pfizer, Novartis, Shire Pharmaceuticals, Allergan Plc, Barr Pharmaceuticals, and Cephalon
Key Topics Covered
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources and Methodology
- Intended Audience
- Geographic Breakdown
- Analyst's Credentials
- Related Reports
Chapter 2 Summary and Highlights Chapter 3 Market and Technology Background
- Market Definition
- Ethics and Cognition and Memory-enhancing Drugs
- Treatments Available for Dementia
- Cholinesterase Inhibitors
- Memantine
- Nondrug Treatments for Dementia
- Availability of Dementia Treatments
- Treatment for Other Symptoms of Dementia Including Aggression and Anxiety
- Side Effects of Cognition and Memory-enhancing Drugs
- Benefits and Side Effects of Consuming Cognition Drugs
- Guidance Given by the American Academy of Neurology
- Current Cognition Enhancers
- Physical Exercise
- Diet and Nutrition
- Social Engagement
- Sleep
- Computer Training Programs
- ADHD Drugs, Symptoms, and Side Effects
- Use of Pharmacological Cognitive Enhancers by Healthy Individuals
- Enhancement of Executive Functions
- Use of Cannabis in Adolescence
- Use of Illicit and Prescription Drugs for Cognitive or Mood Enhancement Among Surgeons
- Study Reported in BMC Medicine in 2013 and Other Studies
- Executive Functions
- Working Memory
- Neuropsychiatric Disorders
- Enhancer Drug Use Trends Among Youth
- Future Prediction of Social Acceptance of Cognition and Memory-enhancing Drugs
- Patent Litigation Claims in the Cognition and Memory-enhancing Drugs Market
- Different Patent Infringement Types
- Clinical Guidelines
- Clinical Guidelines for Cognitive and Behavioral Problems in Dementia
- Clinical Practice Guidelines for Dementia in Australia
- Technology Trends
- Recent Studies Highlighting Potential of Cognition Drugs in Chess
- Market Dynamics
- Drivers
- Restraints
- Opportunities
Chapter 4 Global Cognition and Memory-enhancing Drugs Market Breakdown by Product Type
- ADHD, Attention Deficit Hyperactivity Disorder; MPH, Methylphenidate
- Prohibition of Cognition Enhancers in Healthy Individuals
- Global Cognition and Memory-enhancing Drugs Market
- Aricept
- Exelon
- Reminyl
- Namenda
- Adderall
- Ritalin
- Dexedrin
- Other Cognition and Memory-Enhancing Products
Chapter 5 Global Cognition and Memory-enhancing Drugs Market Breakdown by Application
- Alzheimer's Disease
- Brain Changes Associated with Alzheimer's Disease
- Mild Cognitive Impairment (MCI) - A Potential Precursor to Alzheimer's and Other Dementias
- Recent Case Study on Alzheimer's Disease Drug: 2017
- Case Study on Alzheimer's Disease Drug: 2015
- Mortality and Morbidity Because of Alzheimer's Disease
- Healthcare Expenditure on Alzheimer's Disease
- Emergence of Biomarkers as Diagnostic Tool for Alzheimer's Disease
- Alzheimer's Disease Facts
- Difference between Alzheimer's Disease and Dementia
- Susceptibility Factors for Alzheimer's Disease
- Causes of Alzheimer's Disease
- Diagnosis of Alzheimer's Disease
- Screening of Other Health Conditions of People Suffering from Alzheimer's Disease
- Importance of Comprehensive Clinical Evaluation in the Case of Alzheimer's Disease Patients
- Education Sector
- Sports
- Other Applications
- Cognitive Impairment in People Suffering from Parkinson's Disease
- Treatment of Parkinson's Disease Dementia
- Cognitive Decline in Patients Suffering from Parkinson's Disease Causing Further Complexities
Chapter 6 Global Cognition and Memory-enhancing Drugs Market Breakdown by Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- U.K.
- Germany
- France
- Rest of Europe
- Asia-Pacific
- China
- Japan
- Australia
- India
- Rest of Asia
- ROW
- Brazil
- Turkey
- South Africa
Chapter 7 Patent Review
- Patent Analysis
- Patents Filed in Asia-Pacific
- Patents Filed in North America
Chapter 8 Analysis of Market Opportunities
- Product Approval
- Business Collaboration
Chapter 9 Company Profiles
- ACCELERATED INTELLIGENCE INC.
- Overview
- Products
- ALLERGAN PLC
- Overview
- Products
- ALTERNASCRIPT LLC
- Overview
- Products
- CAMBRIDGE COGNITION
- Overview
- Products
- CERETROPIC
- Overview
- Products
- COGNITION THERAPEUTICS INC.
- Overview
- Products
- COGSTATE LTD.
- Overview
- Products
- HVMN
- Overview
- Products
- NOOTRIMENT
- Overview
- Products
- NOVARTIS AG
- Overview
- ONNIT LABS LLC
- Overview
- Products
- PEAK NOOTROPICS
- Overview
- Products
- PFIZER INC.
- Overview
- Products
- PURELIFE BIOSCIENCE CO., LTD.
- Overview
- Products
- SHIRE
- Overview
- Products
- SUPNOOTROPIC BIO CO., LTD.
- Overview
- Products
- TEVA PHARMACEUTICALS INDUSTRIES LTD. (BARR PHARMACEUTICALS)
- Overview
- Products
Chapter 10 Appendix: Patents, Drugs and Cognitive Enhancers
- List of Patents North America
- List of Patents Applied Globally
- List of Drugs and Cognitive Enhancers
- 1,3-Dimethylamylamine
- 5-HTP
- Acetyl L-Carnitine
- Adrafinil
- Agmatine
- Alpha-GPC
- Alpha-Lipoic Acid
- Aniracetam
- Bacopa Monnieri
- Blueberry
- Boswellia Serrata
- Caffeine
- CDP-Choline
- Celastrus Paniculatus
- Clitoria Ternatea (Shanka Pushpi)
- Cocoa Flavanols
- Coluracetam
- Convolvulus Pluricaulis (Shankhapushpi)
- Creatine
- D-Serine
- Dehydroepiandrosterone
- Dimocarpus Longan
- Emblica Officinalis (Amla)
- Fish Oil (DHA, EPA, Omega-3)
- GABA
- Ginkgo biloba
- Glycine
- Gotu Kola (Centella Asiatica)
- Grape Seed Extract
- Green Tea Catechins
- Hordenine
- Huperzine-A
- Idebenone
- Kava
- Krill Oil
- L-DOPA
- L-Tyrosine
- Magnolia Officinalis
- Melissa Officinalis (Lemon Balm)
- Modafinil
- Morus Alba
- Mucuna Pruriens
- Muira Puama
- Nardostachys Jatamansi
- Nefiracetam
- Nicotine
- Nigella Sativa
- Noopept
- Oxiracetam
- Panax Ginseng
- Phenylethylamine
- Phenylpiracetam
- Phosphatidylserine
- Piracetam
- Polygala Tenuifolia
- Pramiracetam
- PRL-8-53
- Pueraria Lobata
- Pycnogenol
- Pyritinol
- Resveratrol
- Rhodiola Rosea
- S-Adenosyl Methionine
- Sarcosine
- Scutellaria baicalensis
- Sulbutiamine
- Sunifiram
- Theanine
- Uridine
- Vinpocetine
- Vitamin B12
- Yamabushitake
- Yerba Mate
- Zinc
For more information about this report visit https://www.researchandmarkets.com/research/p...ition?w=12
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Central Nervous System Drugs
